Moderna’s stock soars on ‘compelling’ early data for its coronavirus vaccine candidate

The people who were given Moderna Inc.’s (TICKER:MRNA) coronavirus vaccine candidate in a Phase 1 clinical trial developed neutralizing antibodies, a promising finding that has propelled the vaccine into the next phase of clinical testing.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.